CONTINUE TO SITE
OR WAIT null SECS
Search
Spotlight
COVID-19 Update
Analytics
Dosage Forms
Drug Development
Manufacturing
Outsourcing
Quality Systems
COVID-19 Update
Analytics
Dosage Forms
Drug Development
Manufacturing
Outsourcing
Quality Systems
Topic
View More
Analytical Method Development
APIs
Aseptic Processing
Biologic Drugs
Drug Delivery
Equipment
Excipients
Formulation
Packaging
Process Control/PAT
Process Development
QA/QC
Regulatory Action
Supply Chain
Analytical Method Development
APIs
Aseptic Processing
Biologic Drugs
Drug Delivery
Equipment
Excipients
Formulation
Packaging
Process Control/PAT
Process Development
QA/QC
Regulatory Action
Supply Chain
News
All News
Top News
Industry News
Bio/Pharma News
Supplier News
News from Europe
Events
All News
Top News
Industry News
Bio/Pharma News
Supplier News
News from Europe
Events
Publications
All Publications
PharmTech
PharmTech Europe
All Publications
PharmTech
PharmTech Europe
Resources
Front & Center
Pharma Insights
Sponsored eBooks
Sponsored Podcasts
Sponsored Videos
Whitepapers
Front & Center
Pharma Insights
Sponsored eBooks
Sponsored Podcasts
Sponsored Videos
Whitepapers
Webcasts
Marketplace
Subscribe
Enewsletters
Magazine North America
Magazine Europe
Enewsletters
Magazine North America
Magazine Europe
Search
Spotlight
COVID-19 Update
Analytics
Dosage Forms
Drug Development
Manufacturing
Outsourcing
Quality Systems
Topic
See All >
Analytical Method Development
APIs
Aseptic Processing
Biologic Drugs
Drug Delivery
Equipment
Excipients
Formulation
Packaging
Process Control/PAT
Process Development
QA/QC
Regulatory Action
Supply Chain
In the Spotlight-August 2004
August 2, 2004
Pharmaceutical Technology
,
Pharmaceutical Technology-08-02-2004,
Volume 28,
Issue 8
Pharmaceutical Science & Technology Innovations
Related Content:
Analytics
PharmTech Products
Manufacturing
Pharmaceutical Technology-08-02-2004
Bristol Myers Squibb Plans Cell Therapy Manufacturing Site in the Netherlands
Nanoform and Aprecia Explore 3D-Printed Drug Dosage Forms
Vertex Pharmaceuticals and CRISPR Therapeutics Amend Agreement for $1.1 Billion
Related Article >>>